Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018801 (
heart failure
)
72,216
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cardiac failure
affects 1.5% of the adult population and is predominantly caused by myocardial dysfunction secondary to coronary vascular insufficiency. Current therapeutic strategies improve prognosis only modestly, as the primary cause -- loss of normally functioning cardiac myocytes -- is not being corrected. Adult cardiac myocytes are unable to divide and regenerate to any significant extent following injury. New cardiac myocytes are, however, created during embryogenesis from progenitor cells and then by cell division from existing cardiac myocytes. This process is intimately linked to the development of coronary vasculature from progenitors originating in the endothelium, the proepicardial organ and neural crest. In this review, we systematically evaluate approx. 90 mouse mutations that impair heart muscle growth during development. These studies provide genetic evidence for interactions between myocytes, endothelium and cells derived from the proepicardial organ and the neural crest that co-ordinate myocardial and coronary vascular development. Conditional knockout and transgenic rescue experiments indicate that Vegfa, Bmpr1a (ALK3), Fgfr1/2, Mapk14 (p38), Hand1, Hand2, Gata4, Zfpm2 (
FOG2
), Srf and Txnrd2 in cardiac myocytes, Rxra and Wt1 in the proepicardial organ, EfnB2, Tek, Mapk7, Pten, Nf1 and Casp8 in the endothelium, and Bmpr1a and Pax3 in neural crest cells are key molecules controlling myocardial development. Coupling of myocardial and coronary development is mediated by BMP (bone morphogenetic protein), FGF (fibroblast growth factor) and VEGFA (vascular endothelial growth factor A) signalling, and also probably involves hypoxia. Pharmacological targeting of these molecules and pathways could, in principle, be used to recreate the embryonic state and achieve coupled myocardial and coronary vascular regeneration in failing hearts.
...
PMID:Molecular mechanisms controlling the coupled development of myocardium and coronary vasculature. 1676 56
Previous work by us and others has shown that the loss of interaction between GATA4 and
FOG2
protein partners is embryonic lethal due to
heart failure
at embryonic day (E) 13.5; however, the role of this important protein duo in various cardiac compartments (e.g., myocardial, endocardial, or epicardial cells) remains to be understood. Although a dual role (both as an activator and a repressor) for the GATA4-
FOG2
transcriptional complex has been put forward, the specific genes under GATA4-
FOG2
control in the developing heart have remained largely elusive. Since the myocardial-restricted Fog2 re-expression in the Fog2 null embryos is sufficient to extend their life span, identification of GATA4-
FOG2
target genes in cardiomyocytes could shed light on the molecular mechanism of GATA4-
FOG2
action in these cells. We report here that cardiac expression of slow skeletal troponin T (Tnnt1) strictly depends on the physical interaction between GATA4-
FOG2
in the myocardium of both atria and ventricles.
...
PMID:Cardiac expression of Tnnt1 requires the GATA4-FOG2 transcription complex. 1957 15